Multiple costimulatory modalities enhance CTL avidity. - Wikidata - wikimedia - TriplyDB

Multiple costimulatory modalities enhance CTL avidity.

Multiple costimulatory modalities enhance CTL avidity.

http://www.wikidata.org/entity/Q35901490

about

Narrowing the Gap: Preserving Repertoire Diversity Despite Clonal Selection during the CD4 T Cell Response Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances Therapeutic cancer vaccines: past, present, and future Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.Vaccines against human carcinomas: strategies to improve antitumor immune responses.B7 costimulation molecules encoded by replication-defective, vhs-deficient HSV-1 improve vaccine-induced protection against corneal disease Vaccines as monotherapy and in combination therapy for prostate cancer.Strategies to use immune modulators in therapeutic vaccines against cancer Vaccines with enhanced costimulation maintain high avidity memory CTL.Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.Exploiting synergy: immune-based combinations in the treatment of prostate cancer.Immunodomination during peripheral vaccinia virus infection.Viral vector-based therapeutic cancer vaccines A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.Therapeutic cancer vaccines: current status and moving forward.Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression Combining Vaccines with Conventional Therapies for Cancer.Enhancing efficacy of therapeutic vaccinations by combination with other modalities.The current and emerging role of immunotherapy in prostate cancer Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.Role of vaccine therapy in cancer: biology and practice Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.Poxviral vectors for cancer immunotherapy Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Roadmap to a better therapeutic tumor vaccine.Therapeutic cancer vaccines: the latest advancement in targeted therapy.PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells Cancer vaccines: moving beyond current paradigms.Mobilizing the low-avidity T cell repertoire to kill tumors.

P2860

Q26796086-7409AE41-A9E5-4249-AFE3-0FD46B356807 Q26827475-B74BBB5D-7B56-42B0-8C59-969C4015E665 Q26863283-EDF46ECE-CF71-4D41-A036-8844B879C719 Q33604015-D021EC18-EDFF-4EDA-9AE6-8A46BDAC2346 Q33678959-C96C26DC-9726-40E7-A59B-4C2947C2A3E3 Q33703387-16AC4F71-BA3B-4C7C-B994-46EE7D21D960 Q33734281-DBD53D12-4F4A-4889-AE32-819B211EAB0E Q33985984-50C5DBAC-79D1-4CEE-AC95-127762D8B20C Q34039068-AC450801-5F8D-421B-A9BC-AAA79584A4CC Q34275601-D7B0E2A6-D001-4555-85CB-BCFF41300AAB Q34312218-6DAD21DB-5A50-4ACE-80F6-64D1042E7715 Q34312794-556696B7-721E-4405-8B58-AC75913CCE54 Q34403480-3AAA0F5D-C946-46DD-A983-0B2369076B4F Q34492813-6616298D-23B4-40CB-9AD2-75368521DB86 Q34557531-F84D8B78-91B7-47C9-BC62-30E8D185254C Q34634220-DD95F4E6-C157-4D5D-B20A-1EC4C008B2D3 Q34687216-5918A7AA-F138-4CED-90B0-3FE6599E6EDE Q34697921-60409FE3-B2DF-49F5-970A-A2ADE7D9A3EC Q35515080-E7F8A967-59DB-4F9C-A09E-78DC783E9D28 Q35582228-5E26279A-B0FF-451F-9210-CA97C0A15B3F Q35886767-7F56B115-9E13-4A24-A30B-3D67CB0BA362 Q35894347-AD1C243A-54E5-496B-AB9E-42D063772E4E Q36060263-516B317F-98F3-4FC7-B5B7-A64B55D07664 Q36082331-9EDB036E-3036-4D54-AE62-F5DF15FEAE8D Q36113943-E410D183-48E7-4A7B-9290-C9EB14AFF5C4 Q36249922-950B570A-7DD5-438A-BE90-411A85F40CBB Q36254081-B8494D5C-2D9B-4044-BA40-B889B16DE5C5 Q36256420-EC0BBD0F-097F-469C-91C7-79D8878F5D5C Q36285594-B2A37D11-4612-4E22-AC2B-9C944033D540 Q36350388-4F635A6D-E177-402D-B44C-EBDFF994DD0D Q36388538-1D3DFFF4-F3C9-4A47-9E76-A8C738076A39 Q36456190-8587743C-63AA-4CC1-9C5E-EEE44A2FEA33 Q36456487-E0496D49-7783-4EA7-9150-5CFA62E357DA Q36567448-42F07825-479B-476F-BE79-A7CB63601C68 Q36684496-F2B83EBD-B401-45F6-9082-78ED30158ADD Q36695629-B6DC68E0-8BA7-460A-9540-E759841B8B9C Q36764939-B1C34C21-88E5-4B73-AA0C-4957991BEB37 Q36823732-0C21D1B2-84B6-41B4-B746-4A41FE3FA72A Q36868126-E1BED6F0-0EC9-4909-80D9-037A6B658895 Q36891310-1B294AB8-31D0-4487-96C9-38190E72DFD6

P2860

Multiple costimulatory modalities enhance CTL avidity.

http://www.wikidata.org/entity/Q35901490

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Multiple costimulatory modalities enhance CTL avidity.

@ast

Multiple costimulatory modalities enhance CTL avidity.

@en

type

label

Multiple costimulatory modalities enhance CTL avidity.

@ast

Multiple costimulatory modalities enhance CTL avidity.

@en

prefLabel

Multiple costimulatory modalities enhance CTL avidity.

@ast

Multiple costimulatory modalities enhance CTL avidity.

@en

P1433

Q35901490-4FB6A193-E07A-4654-868F-DEFC29672E3E

P1476

Q35901490-6E22A76F-7453-4D69-AC65-113D566FE04E

P2093

Q35901490-081C4BD7-2044-44F2-8ED6-489D8D037AC1

Q35901490-5CE2F5CE-28C1-460D-B5D9-E134ABD287F8

Q35901490-676BCA9F-B5B5-4E78-AE9F-B5AECD687586

Q35901490-99DF380C-6E14-4C27-83C6-23EF29800211

Q35901490-A1CF7D1D-674D-46C1-8EF6-73EFDCC4C533

P2860

Q35901490-04369920-1F01-4CF2-B8CD-5F4A5300F3D4

Q35901490-08A0A11D-376A-4DF9-B43F-512E6525F259

Q35901490-0ECC75D2-9F5E-4F0D-81FC-D606D19A3303

Q35901490-21E99C88-6C4E-44C5-AD59-2183467C5CE2

Q35901490-2370B74E-E1A1-4919-9E51-105C8F379CA4

Q35901490-2D5C9FA8-97C8-4F4E-A7D4-65C93FF255B5

Q35901490-2E5B8067-AC93-4385-AED3-C8A4DE51B018

Q35901490-54A129E8-F6D6-4B0F-ABDA-C12AB820DB5D

Q35901490-5D013AAD-A446-44C5-AEB6-5954D3121435

Q35901490-66A288ED-8AC0-467E-BF60-06C8287C4CEF

P304

Q35901490-D2809A43-8017-4DB4-90A7-FFE1531DCDE7

P31

Q35901490-1A713382-091F-409A-8EAA-773AFD3AE4CD

P356

Q35901490-D8C5662C-E9FB-4EFC-819A-1D987187CCB1

P407

Q35901490-82B0BCA5-A878-4097-8BEB-31D35AEA1E3C

P433

Q35901490-0FC661EC-D5C6-4F1F-80BF-F861404770E3

P478

Q35901490-CECD6646-968A-4AC6-9EAF-7CFAE143A939

P577

Q35901490-9FBDB707-A6C3-4905-A318-41EDC31F1CE6

P5875

Q35901490-D133FA64-A70E-4E67-919F-2813FFBA11CE

P698

Q35901490-06069847-4F31-4BB6-9DBC-9058A7D46D30

P932

Q35901490-5BB05E28-97C2-4532-8DC6-45263B2E1E64

P356

JIMMUNOL.174.10.5994

P1433

Journal of Immunology

P1476

Multiple costimulatory modalities enhance CTL avidity.

@en

P2093

Charlie T Garnett

http://www.w3.org/2001/XMLSchema#string

Chie Kudo-Saito

http://www.w3.org/2001/XMLSchema#string

James W Hodge

http://www.w3.org/2001/XMLSchema#string

Jeffrey Schlom

http://www.w3.org/2001/XMLSchema#string

Mala Chakraborty

http://www.w3.org/2001/XMLSchema#string

P2860

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Enhancement of antitumor immunity by CTLA-4 blockade

Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.

Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions

Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.

Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections.

A novel CD8-independent high-avidity cytotoxic T-lymphocyte response directed against an epitope in the phosphoprotein of the paramyxovirus simian virus 5

Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life

P304

5994-6004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.174.10.5994

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7862078

http://www.w3.org/2001/XMLSchema#string

P698

15879092

http://www.w3.org/2001/XMLSchema#string

P932

1924685

http://www.w3.org/2001/XMLSchema#string